Literature DB >> 27614992

Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy.

Basilio Passamonti1, Daniela Gustinucci1, Paolo Giorgi Rossi2,3, Elena Cesarini1, Simonetta Bulletti1, Angela Carlani1, Nadia Martinelli1, Massimo Broccolini1, Valentina D'Angelo1, Maria Rosaria D'Amico1, Eugenio Di Dato1, Paola Galeazzi1, Morena Malaspina1, Nicoletta Spita1, Beatrice Tintori1, Maria Donata Giaimo4.   

Abstract

Objective To present the results of the first and second round human papilloma virus (HPV)-based screening programme in the Umbria region after three years. Methods From August 2010 to November 2011, the entire female population aged 35-64 in a local health district was invited for HPV testing (HPV-DNA cobas4800 on a liquid-based cytology sample). HPV-negative women were re-invited after three years. For HPV-positive women, a slide was prepared and interpreted. Positive cytologies were referred to colposcopy; negatives were referred to repeat HPV after one year. If HPV was persistently positive, women were referred to colposcopy; if negative, to normal screening. Indicators of the first and second round are compared with those of cytology screening in the same area in the preceding three years. Results Participation was 56.5%, the same as cytology (56.6%). HPV-positivity was 6.4% (396/6272), cytology triage positivity was 35.6%; 251 cytology negative women were referred to one-year HPV retesting, 84.1% complied, and 55.5% were positive. Total colposcopy referral was 4.1%, and for cytology 1%. The detection rate for cervical intraepithelial neoplasia grade 2 or more severe was 10‰, compared with 3.7‰ using cytology. After three years, HPV-positivity was 3.4% (129/3831), overall colposcopy referral was 2.3% (most at one-year follow-up), and detection rate was 0.5/1000. Conclusions The first round detection rate was more than twice that of cytology screening, while colposcopy referral increased fourfold. At the second round, the detection rate decreased dramatically, showing that longer interval and more conservative protocols are needed.

Entities:  

Keywords:  Screening; cervical cancer; human papilloma virus

Mesh:

Year:  2016        PMID: 27614992     DOI: 10.1177/0969141316663580

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  8 in total

1.  HPV-based cervical cancer screening- facts, fiction, and misperceptions.

Authors:  Nicolas Wentzensen; Marc Arbyn
Journal:  Prev Med       Date:  2017-02-06       Impact factor: 4.018

2.  Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.

Authors:  Paolo Giorgi Rossi; Simonetta Bisanzi; Elena Allia; Alessandra Mongia; Francesca Carozzi; Anna Gillio-Tos; Laura De Marco; Guglielmo Ronco; Daniela Gustinucci; Annarosa Del Mistro; Helena Frayle; Anna Iossa; Giulia Fantacci; Giampaolo Pompeo; Elena Cesarini; Simonetta Bulletti; Basilio Passamonti; Martina Rizzi; Maria Gabriella Penon; Alessandra Barca; Maria Benevolo
Journal:  J Clin Microbiol       Date:  2017-01-18       Impact factor: 5.948

3.  Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.

Authors:  S Gori; J Battagello; D Gustinucci; C Campari; M Zorzi; H Frayle; B Passamonti; G Sartori; S Bulletti; C Fodero; E Cesarini; R Faggiano; A Del Mistro
Journal:  BJOG       Date:  2021-01-12       Impact factor: 6.531

4.  Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16/18 and cytology.

Authors:  Yuan-Yuan Gu; Guan-Nan Zhou; Qing Wang; Jing-Xin Ding; Ke-Qin Hua
Journal:  Clin Epigenetics       Date:  2020-04-21       Impact factor: 6.551

5.  Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain.

Authors:  R Ibáñez; M Mareque; R Granados; D Andía; M García-Rojo; J C Quílez; I Oyagüez
Journal:  BMC Womens Health       Date:  2021-04-26       Impact factor: 2.809

6.  Investigating the decrease in participation in the Dutch cervical cancer screening programme: The role of personal and organisational characteristics.

Authors:  Clare A Aitken; Sylvia Kaljouw; Albert G Siebers; Matilde Bron; Anne Morssink; Folkert J van Kemenade; Inge M C M de Kok
Journal:  Prev Med Rep       Date:  2021-02-20

7.  Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.

Authors:  Helena Lamin; Carina Eklund; Klara Miriam Elfström; Agneta Carlsten-Thor; Maria Hortlund; Kristina Elfgren; Sven Törnberg; Joakim Dillner
Journal:  BMJ Open       Date:  2017-05-30       Impact factor: 2.692

8.  Clinical Performance of Human Papillomavirus (HPV) Testing versus Cytology for Cervical Cancer Screening: Results of a Large Danish Implementation Study.

Authors:  Louise T Thomsen; Susanne K Kjær; Christian Munk; Kirsten Frederiksen; Dorthe Ørnskov; Marianne Waldstrøm
Journal:  Clin Epidemiol       Date:  2020-02-21       Impact factor: 4.790

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.